{"id":"adalimumab-biosimilar","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"5-10","effect":"Headache"},{"rate":"<1","effect":"Tuberculosis reactivation"},{"rate":"2-5","effect":"Serious infections"},{"rate":"low, similar to reference","effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a fully human monoclonal antibody that binds with high affinity to soluble and membrane-bound TNF-alpha, preventing its interaction with TNF receptors on immune cells. This blocks the inflammatory cascade driven by TNF-alpha, reducing systemic inflammation and immune activation in autoimmune and inflammatory conditions. As a biosimilar, it is a highly similar version of the reference biologic adalimumab (Humira) with comparable efficacy and safety.","oneSentence":"Adalimumab biosimilar is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:13.991Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Plaque psoriasis"},{"name":"Hidradenitis suppurativa"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07486843","phase":"PHASE4","title":"Preventing Structural Damage in Early Psoriatic Arthritis","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-03-16","conditions":"Psoriatic Arthritis (PsA)","enrollment":108},{"nctId":"NCT05913817","phase":"","title":"The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.","status":"COMPLETED","sponsor":"Jamp Pharma Corporation","startDate":"2023-01-09","conditions":"Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis","enrollment":324},{"nctId":"NCT05803187","phase":"","title":"Clinical Study of Stage IV Psoriasis in Children With Geleli","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2023-04-05","conditions":"Plaque Psoriasis","enrollment":80},{"nctId":"NCT05633771","phase":"","title":"Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","startDate":"2023-02-16","conditions":"Inflammatory Bowel Disease","enrollment":562},{"nctId":"NCT07221890","phase":"NA","title":"A Trial of Academic Detailing to Promote Prescribing of Biosimilars","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-11-06","conditions":"Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD)","enrollment":1325},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT05598684","phase":"","title":"SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases","status":"UNKNOWN","sponsor":"Fresenius Kabi, France","startDate":"2022-11-24","conditions":"Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis","enrollment":600},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT06291948","phase":"PHASE1","title":"A Clinical Study With Adalimumab Biosimilar","status":"COMPLETED","sponsor":"Laboratorios Richmond S.A.C.I.F.","startDate":"2022-08-01","conditions":"Pharmacokinetics, Safety Issues","enrollment":150},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT05527444","phase":"PHASE4","title":"The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-15","conditions":"Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT05051943","phase":"","title":"A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response","status":"COMPLETED","sponsor":"Fresenius Kabi","startDate":"2020-09-29","conditions":"Crohn Disease, Ulcerative Colitis, Psoriasis","enrollment":754},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT03266471","phase":"","title":"Cytokines and Genes in Therapeutic Response in Crohn's Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-10-13","conditions":"Inflammatory Bowel Diseases","enrollment":96},{"nctId":"NCT03662919","phase":"","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","status":"COMPLETED","sponsor":"Biogen","startDate":"2018-07-02","conditions":"Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic","enrollment":2274},{"nctId":"NCT05172817","phase":"PHASE2, PHASE3","title":"Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients","status":"UNKNOWN","sponsor":"Institute for Developing Science and Health Initiatives, Bangladesh","startDate":"2021-06-02","conditions":"Pharmacokinetics, Safety, Efficacy","enrollment":200},{"nctId":"NCT05427942","phase":"","title":"Yuflyma® (Adalimumab), Patient Experience After Switching","status":"UNKNOWN","sponsor":"Celltrion HealthCare France","startDate":"2022-06-03","conditions":"Rheumatoid Arthritis, Ankylosing Spondylarthritis, Axial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis","enrollment":300},{"nctId":"NCT03357939","phase":"PHASE1","title":"Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-01-12","conditions":"Immune System Disorder","enrollment":220},{"nctId":"NCT03983876","phase":"PHASE1","title":"PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-07-01","conditions":"Phase 1","enrollment":207},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT02472912","phase":"PHASE1","title":"Adalimumab PK Bioequivalence Study to EU and US Sourced Humira","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":270},{"nctId":"NCT05240859","phase":"","title":"Real World Study of a Adalimumab Biosimilar (Geleli) in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-02-22","conditions":"Rheumatoid Arthritis","enrollment":1600},{"nctId":"NCT05190484","phase":"","title":"bIosimilar of aDalimumab, an European evAluation","status":"UNKNOWN","sponsor":"Fresenius Kabi","startDate":"2022-04-30","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":1050},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT02762955","phase":"PHASE3","title":"Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-12","conditions":"Psoriasis","enrollment":344},{"nctId":"NCT03890445","phase":"","title":"Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease","status":"COMPLETED","sponsor":"Sandoz","startDate":"2019-06-24","conditions":"Crohn´s Disease","enrollment":63},{"nctId":"NCT04045782","phase":"PHASE4","title":"Evaluation of the Safety and Effectiveness of Switching From Humira® to Imraldi® in Flanders","status":"COMPLETED","sponsor":"Pieter Dewint, MD PhD","startDate":"2019-08-19","conditions":"Inflammatory Bowel Diseases","enrollment":130},{"nctId":"NCT04808739","phase":"","title":"Adalimumab Biosimilar in Clinical Practice","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-06-01","conditions":"Psoriasis","enrollment":604},{"nctId":"NCT04131322","phase":"PHASE4","title":"Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.","status":"TERMINATED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-10-10","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":24},{"nctId":"NCT04422171","phase":"","title":"A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2020-06-19","conditions":"IBD Patients, Originator Treatment, Biosimilar, Switch Back","enrollment":400},{"nctId":"NCT03849404","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-02-20","conditions":"Plaque Psoriasis","enrollment":413},{"nctId":"NCT04439929","phase":"PHASE1","title":"Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects","status":"COMPLETED","sponsor":"Turgut İlaçları A.Ş.","startDate":"2019-07-17","conditions":"Healthy Participants","enrollment":168},{"nctId":"NCT04018599","phase":"PHASE1","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2019-07-15","conditions":"Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis","enrollment":216},{"nctId":"NCT04147026","phase":"NA","title":"Prediction Medical Device for Rheumatoid Arthritis (PREDIRA)","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2019-12-16","conditions":"Arthritis, Rheumatoid","enrollment":180},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT03775824","phase":"","title":"Faecal Analyses in Rheumatoid Arthritis Therapy","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-08-01","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT02405780","phase":"PHASE3","title":"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","startDate":"2015-06-10","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT02581345","phase":"PHASE3","title":"Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2015-09","conditions":"Chronic Plaque Psoriasis, Psoriasis","enrollment":572},{"nctId":"NCT02722044","phase":"PHASE3","title":"Usability of an AI for M923 in Subjects With Moderate to Severe RA","status":"COMPLETED","sponsor":"Momenta Pharmaceuticals, Inc.","startDate":"2016-04","conditions":"Rheumatoid Arthritis","enrollment":33},{"nctId":"NCT02927353","phase":"PHASE1","title":"A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects","status":"COMPLETED","sponsor":"Meiji Seika Pharma Co., Ltd.","startDate":"2016-08","conditions":"Healthy Volunteer","enrollment":180},{"nctId":"NCT02167139","phase":"PHASE3","title":"A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Rheumatoid Arthritis","enrollment":544},{"nctId":"NCT02016105","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-12","conditions":"Plaque Type Psoriasis","enrollment":465}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":219,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AVT02"],"phase":"phase_3","status":"active","brandName":"Adalimumab biosimilar","genericName":"Adalimumab biosimilar","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab biosimilar, also known as GP2017 Adalimumab, is a monoclonal antibody that works by inactivating tumor necrosis factor, a protein involved in inflammation. It is used to treat various chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}